Ligand Pharm (LGND)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 174,927 | 139,376 | 67,669 | 47,989 | 72,307 |
| Marketable Securities | 581,386 | 537,562 | 177,351 | 160,912 | 193,883 |
| Receivables | 61,047 | 58,096 | 52,392 | 42,831 | 42,449 |
| Inventories | 9,126 | 11,900 | 15,489 | 14,614 | 14,114 |
| Other current assets | 5,785 | 6,986 | 40,044 | 42,970 | 8,806 |
| TOTAL | $832,271 | $753,920 | $352,945 | $309,316 | $331,559 |
| Non-Current Assets | |||||
| PPE Net | N/A | 3,466 | 3,632 | 3,623 | N/A |
| Investments And Advances | 167,951 | 355,053 | 10,908 | 10,908 | 10,908 |
| Intangibles | 326,979 | 335,076 | 351,674 | 359,932 | 371,898 |
| Other Non-Current Assets | 233,436 | 29,257 | 229,445 | 221,656 | 227,409 |
| TOTAL | $728,366 | $722,852 | $595,659 | $596,119 | $610,215 |
| Total Assets | $1,560,637 | $1,476,772 | $948,604 | $905,435 | $941,774 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 3,238 | 3,679 | 8,584 | 5,366 | 5,233 |
| Accrued Expenses | 31,453 | 24,084 | 17,464 | 23,537 | 27,906 |
| Other current liabilities | 422 | 403 | 37,157 | 26,993 | 1,508 |
| TOTAL | $37,447 | $30,539 | $64,734 | $58,683 | $37,112 |
| Non-Current Liabilities | |||||
| Deferred Revenues | N/A | N/A | 111 | 101 | N/A |
| Other Non-Current Liabilities | 469,959 | 473,389 | 23,095 | 21,839 | 39,453 |
| TOTAL | $505,978 | $496,062 | $55,341 | $51,218 | $74,223 |
| Total Liabilities | $543,425 | $526,601 | $120,075 | $109,901 | $111,335 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 19,941 | 19,682 | 19,597 | 19,294 | 19,255 |
| Common Shares | 20 | 20 | 20 | 20 | 20 |
| Retained earnings | 608,088 | 578,215 | 461,380 | 456,533 | 498,984 |
| Other shareholders' equity | 8,455 | 9,322 | 8,494 | -1,563 | -5,942 |
| TOTAL | $1,017,212 | $950,171 | $828,529 | $795,534 | $830,439 |
| Total Liabilities And Equity | $1,560,637 | $1,476,772 | $948,604 | $905,435 | $941,774 |